By Mill Chart
Last update: Nov 6, 2023
Take a closer look at EXELIXIS INC (NASDAQ:EXEL), an affordable growth stock uncovered by our stock screener. NASDAQ:EXEL boasts strong growth prospects and excels in financial health indicators, all while maintaining a reasonable valuation. Let's break it down further.
ChartMill assigns a proprietary Growth Rating to each stock. The score is computed by evaluating various growth aspects, like EPS and revenue growth. We take into account the history as well as the estimated future numbers. NASDAQ:EXEL was assigned a score of 7 for growth:
To assess a stock's valuation, ChartMill utilizes a Valuation Rating on a scale of 0 to 10. This comprehensive assessment considers various valuation aspects, comparing price to earnings and cash flows, while factoring in profitability and growth. NASDAQ:EXEL has achieved a 6 out of 10:
ChartMill employs a unique Health Rating system for all stocks. This rating, ranging from 0 to 10, is determined by analyzing various liquidity and solvency ratios. For NASDAQ:EXEL, the assigned 7 for health provides valuable insights:
ChartMill's Profitability Rating offers a unique perspective on stock analysis, providing scores from 0 to 10. These ratings consider a wide range of profitability metrics and margins, both in comparison to industry peers and on their own merits. For NASDAQ:EXEL, the assigned 7 is a significant indicator of profitability:
More Affordable Growth stocks can be found in our Affordable Growth screener.
Check the latest full fundamental report of EXEL for a complete fundamental analysis.
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
EXELIXIS INC
NASDAQ:EXEL (4/18/2024, 7:00:02 PM)
After market: 23.12 +0.63 (+2.8%)22.49
-0.38 (-1.66%)
Some of the best opportunities can be found in dips in some of the top biotech stocks to buy. In fact, here are three.
Phenomenal deals can still be found, even with the Nasdaq Composite climbing to a new all-time high.
These stocks are worth buying in most months of the year.
With excellent financial health and great prospects, these three biotech stocks just may be the the next stars of the sector.
The growth-driven Nasdaq Composite has entered a new bull market, but plain-as-day deals can still be found.
You don't need to be a millionaire to get started. Investing on a budget can work, too.
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END
The best biotech stocks to buy offer consistent growth opportunities and resist the influence of singular drug successes.